Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 2,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $52.88, for a total value of $105,760.00. Following the completion of the transaction, the vice president directly owned 29,891 shares in the company, valued at approximately $1,580,636.08. The trade was a 6.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Patrick Lamy also recently made the following trade(s):

• On Friday, June 20th, Patrick Lamy sold 875 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.59, for a total transaction of $47,766.25.
• On Monday, June 16th, Patrick Lamy sold 2,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.14, for a total transaction of $108,280.00.
• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.31, for a total value of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.00, for a total value of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total value of $339,920.00.

Akero Therapeutics Trading Up 0.3%

NASDAQ:AKRO traded up $0.13 on Friday, reaching $52.01. The stock had a trading volume of 404,821 shares, compared to its average volume of 1,048,061. Akero Therapeutics, Inc. has a 12-month low of $21.02 and a 12-month high of $58.40. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -26.67 and a beta of -0.15. The firm's fifty day moving average is $48.66 and its two-hundred day moving average is $42.57. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.80 and a quick ratio of 16.80.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AKRO. Bank of America lifted their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Citigroup decreased their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Northwest & Ethical Investments L.P. acquired a new position in shares of Akero Therapeutics during the 1st quarter valued at about $32,000. GF Fund Management CO. LTD. purchased a new stake in Akero Therapeutics in the fourth quarter valued at approximately $41,000. Sterling Capital Management LLC increased its position in Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock worth $67,000 after purchasing an additional 390 shares during the last quarter. Finally, Quarry LP purchased a new position in Akero Therapeutics during the fourth quarter worth approximately $83,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.